The GRADE system can be used to grade the quality of evidence and strength of recommendations for diagnostic tests or strategies. This article explains how patient-important outcomes are taken into account in this process aHolger J Schünemann professor,
In this fourth article of the five part series, we describe how guideline developers are using GRADE to rate the quality of evidence and move from evidence to a recommendation for diagnostic tests and strategies. Although recommendations on diagnosis share the fundamental logic of recommendations for other interventions, they present unique challenges. We will describe why guideline panels should be cautious when they use evidence of the accuracy of tests ("test accuracy") as the basis for recommendations and why evidence of test accuracy often provides low quality evidence for making recommendations.
Testing makes a variety of contributions to patient care Clinicians use tests-including signs and symptoms, imaging, and biochemistry-to identify physiological derangements, establish prognosis, monitor illness, and diagnose. 1 This article focuses on diagnosis: the use of tests to establish the presence or absence of a disease (such as tuberculosis), target condition (such as iron deficiency), or syndrome (such as Cushing's syndrome).
Clinicians often use diagnostic tests as a package or strategy. For example, in managing patients with apparently operable lung cancer, clinicians may proceed directly to thoracotomy or apply a strategy of imaging the brain, bone, liver, and adrenal glands, with subsequent management depending on the results. Thus, one can often think of evaluating or recommending not a single test, but a diagnostic strategy. Guideline panels considering a diagnostic test or strategy should begin by identifying the patients, diagnostic intervention (strategy), comparison, and outcomes of interest (box). 2 3 Test accuracy is a surrogate for outcomes important to patients The main contribution of this article is that it presents a framework for thinking about the quality of evidence for diagnostic tests in terms of their impact on outcomes important to patients ("patient-important outcomes"). Usually, when clinicians think about diagnostic tests, they focus on accuracy (sensitivity and specificity); that is, how well the test classifies patients correctly as having or not having a disease. The underlying assumption is, however, that obtaining a better idea of whether a target condition is present or absent will result in improved outcome. For patients who present with apparently operable lung cancer, the presumption is that additional tests will spare patients the morbidity and early mortality associated with futile thoracotomy. The example of computed tomography for coronary artery disease in the box illustrates another common rationale for a new test: replacement of another test (coronary computed tomography instead of conventional angiography) to avoid complications associated with a more invasive and expensive alternative. 6 The best way to assess any diagnostic strategy-but in particular new strategies with putative superior accuracy-is a randomised controlled trial in which investigators randomise patients to experimental or control diagnostic approaches and measure mortality, morbidity, symptoms, and quality of life (figure). 7 When diagnostic intervention studies-ideally randomised controlled trials but also observational studies-comparing the impact of alternative diagnostic
RAtING quALItY of EvIDENcE AND StRENGth of REcommENDAtIoNS
This is the fourth in a series of five articles that explain the GRADE system for rating the quality of evidence and strength of recommendations Authors continued on next page either welcome reassurance that a patient will not have the condition or the ability to plan for the future knowing that he or she will develop the condition. The ability to plan is analogous to an effective treatment, and the benefits of planning need to be balanced against the downsides of receiving an early diagnosis. [15] [16] [17] We will now describe factors that influence the balance between desirable and undesirable consequences, focusing on the quality of evidence. We will use a simplified approach that classifies test results into yielding true positives, true negatives, false positives, and false negatives.
Judgment about quality of underlying evidence Study design and limitations (risk of bias) GRADE's four categories of quality of evidence represent a gradient of confidence in estimates of the effect of a diagnostic test strategy on patient-important outcomes. 13 Table 2 describes how GRADE deals with the particular challenges of judging the quality of evidence of alternative diagnostic strategies. As we have noted, randomised trials of alternative diagnostic approaches represent the ideal study design for informing recommendations. Nevertheless, in the GRADE system, valid studies of test accuracy also start as high quality in the diagnostic framework. Such studies are, however, vulnerable to limitations and often provide low quality evidence for recommendations as a result of the indirect evidence they usually offer on impact on patientimportant outcomes.
Valid studies of diagnostic test accuracy include representative and consecutive patients in whom legitimate diagnostic uncertainty exists-that is, the sort of patients to whom clinicians would apply the test in the course of regular clinical practice. If studies fail this criterionand, for example, enrol severe cases and healthy strategies on patient-important outcomes are available, guideline panels can use the GRADE approach described in previous articles in this series. 12 13 When such studies are not available, guideline panels must focus on studies of test accuracy and make inferences about the likely impact on patient-important outcomes. 14 The key questions are whether a reduction in false negatives (cases missed) or false positives and corresponding increases in true positives and true negatives will occur, how accurately similar or different patients are classified by the alternative testing strategies, and what outcomes occur in both patients labelled as cases and those labelled as not having disease. Table  1 presents examples that illustrate these questions.
Using indirect evidence to make inferences about impact on patient-important outcomes Inferring from data on accuracy that a diagnostic test or strategy improves patient-important outcomes requires the availability of effective treatment. 1 Alternatively, even without an effective treatment, an accurate test may be beneficial if it reduces test related adverse effects or anxiety, or if confirming a diagnosis improves patients' wellbeing through the prognostic information it imparts.
For instance, the results of genetic testing for Huntington's chorea, an untreatable condition, may provide
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Example of a sensible clinical question
In patients in whom coronary artery disease is suspected, does multislice spiral computed tomography of coronary arteries as a replacement for conventional invasive coronary angiography reduce complications with acceptable rates of false negatives associated with coronary events and false positives leading to unnecessary treatment and complications? 4 5 focusing on accuracy 
Outcomes
Similar criteria-Panels assessing diagnostic tests often face an absence of direct evidence about impact on patientimportant outcomes. They must make deductions from studies of diagnostic tests about the balance between the presumed influences on patient-important outcomes of any differences in true and false positives and true and false negatives in relation to complications and costs of the test. Therefore, accuracy studies typically provide low quality evidence for making recommendations owing to indirectness of the outcomes, similar to surrogate outcomes for treatments Patient populations, diagnostic test, comparison test, and indirect comparisons Similar criteria-Quality of evidence can be reduced if important differences exist between populations studied and those for whom recommendation is intended (in previous testing, spectrum of disease or comorbidity); if important differences exist in tests studied and diagnostic expertise of people applying them in studies compared with settings for which recommendations are intended; or if tests being compared are each compared with a reference (gold) standard in different studies and not directly compared in same studies Important inconsistency in study results Similar criteria-For accuracy studies, unexplained inconsistency in sensitivity, specificity, or likelihood ratios (rather than relative risk or mean differences) can reduce quality of evidence Imprecise evidence Similar criteria-For accuracy studies, wide confidence intervals for estimates of test accuracy or true and false positive and negative rates can reduce quality of evidence High probability of publication bias Similar criteria-High risk of publication bias (for example, evidence from small studies for new intervention or test, or asymmetry in funnel plot) can lower quality of evidence for patient-important outcomes for true positives, false positives, and true negatives (table 1) . However, some uncertainty about the extent to which limitations in test accuracy will have deleterious consequences on patientimportant outcomes for false negatives led to downgrading the quality of evidence from high to moderate (table 5 see bmj.com). Unexplained heterogeneity in the results across studies further reduced the quality of evidence for all outcomes. Major uncertainty about the impact of false negative tests on patient-important outcomes would have led to downgrading the quality of evidence from high to low for the other examples in table 1.
Arriving at a recommendation
The balance of presumed patient-important outcomes as the result of true and false positives and negatives with test complications determine whether a guideline panel makes a recommendation for or against applying a test. 12 Other factors influencing the strength of a recommendation include the quality of the evidence, the uncertainty about values and preferences associated with the tests and presumed patient-important outcomes, and cost.
Coronary computed tomography scanning avoids the adverse consequences of invasive angiography, which can include myocardial infarction and death. These consequences are, however, very rare. As a result, a guideline panel evaluating coronary computed tomo graphy as a replacement test for coronary angiography could, despite its lower cost, make a weak recommendation against its use in place of invasive coronary angiography. This recommendation follows from the large number of false positives and the risk of coronary artery disease (tables 3 and 4). True positive results will lead to the administration of treatments of known effectiveness (drugs, angioplasty and stents, bypass surgery), and true negative results will spare patients the possible adverse effects of the reference standard test. On the other hand, false positive results will result in adverse effects (unnecessary drugs and interventions, including the possibility of follow-up angioplasty) without apparent benefit, and false negatives will result in patients not receiving the benefits of available interventions that help to reduce the subsequent risk of coronary events.
Thus, it is relatively certain that minimising false positives and false negatives will benefit patients. The impact of inconclusive test results is less clear, but they are clearly undesirable. Furthermore, the complications of invasive angiography-infarction and death-although rare, are undoubtedly important. When guideline panels balance the desirable and undesirable consequences of diagnostics tests, they should consider the importance of these consequences for patients. In this example of patients with a relatively low probability for coronary artery disease, computed tomography scanning results in a large number of false positives leading to unnecessary anxiety and further testing (table 4) . It also leads to missing about 1% (false negatives) of patients who have coronary artery disease.
Guideline panels considering questions of diagnosis also face the same sort of challenges regarding indirectness as do panels making recommendations for other interventions. 2 Test accuracy may vary across populations of patients, so panels need to consider how well the populations included in the studies correspond to the population that is the focus of the recommendations. Similarly, panels need to consider how comparable new tests and reference tests are to the tests used in the settings for which the recommendations are made. Finally, when evaluating two or more alternative new tests or strategies, panels need to consider whether these diagnostic strategies were compared directly (in one study) or indirectly (in separate studies) with a common (reference) standard. [25] [26] [27] Arriving at a bottom line for study quality Table 5 shows the evidence summary and the quality assessment for all critical outcomes of computed tomography angiography as a replacement for invasive angiography. Little or no uncertainty exists about the directness of the evidence (for test results) False negative results** 8 9
Inconclusive results † † § § -5
Complications ‡ ‡ § § -5
Cost § § -5
All results given per 1000 patients tested for prevalence of 20% and likelihood ratios shown in table 3. *Assuming that the reference standard, angiography, does not yield false positives or false negatives. †On a 9 point scale, GRADE recommends classifying these outcomes as not important (score 1-3), important (4-6), and critical (7-9) to a decision. 13 18 19 ‡Important because mandates drugs, angioplasty and stents, bypass surgery. §Important because spares patients unnecessary interventions associated with adverse effects. ¶Important because patients are exposed to unnecessary potential adverse effects from drugs and invasive procedures. **Important because increase risk of coronary events as a result of patients not receiving efficacious treatment.
† †Uninterpretable, indeterminate, or intermediate test results; important because generate anxiety, uncertainty as to how to proceed, further testing, and possible negative consequences of either treating or not treating. ‡ ‡Not reliably reported; important because although rare, they can be serious. § §Although the data for these consequences are not reported for simplicity or because they are not exactly known on the basis of the available data, they are important.
missing patients with coronary artery disease who could be treated effectively (false negatives). It also follows from the evidence for the new test being only low quality and the consideration of values. Despite the general preference for less invasive tests with lower risks of complications, most patients would probably favour the more invasive approach (angiography), given the risks associated with false positives and negatives.
Conclusion
As for other management recommendations, the GRADE approach to grading the quality of evidence and strength of recommendations for diagnostic tests provides a comprehensive and transparent approach for developing these recommendations. Recognising that test results are surrogates for patient-important outcomes is central to this approach. The application of the approach requires a shift in clinicians' thinking to clearly recognise that, whatever their accuracy, diagnostic tests are of value only if they result in improved outcomes for patients.
